(Press-News.org) By the time patients start seeking care for multiple sclerosis (MS), the disease has already been damaging their brains for years. But until recently, scientists didn’t understand which brain cells were being targeted or when the injury began.
Now, by analyzing thousands of proteins found in the blood, scientists at UC San Francisco have created the clearest picture yet of when the disease attacks the myelin sheath that covers the nerve fibers. It shows that the immune system begins attacking the brain even earlier than previously had been thought.
The study measured debris from these attacks in a person’s blood, along with the signals that coordinate the immune system to go on the attack. It lays out, for the first time, the sequence of events that eventually lead to the disease.
The discovery could lead to new ways to diagnose multiple sclerosis — and possibly one day prevent it.
MS first attacks the fatty myelin sheath, and a year later, it’s possible to see the breakdown of nerve fibers themselves.
Among the many immune signaling proteins that were elevated in the early stage of the disease, one protein stood out: IL-3. It plays an important role in this early phase when the central nervous system is suffering significant damage, but the patient doesn’t yet feel it. IL-3 is known for recruiting immune cells to the brain and spinal cord, where they attack nerve cells.
“We think our work opens numerous opportunities for diagnosing, monitoring, and possibility treating MS,” said Ahmed Abdelhak, MD, assistant professor of Neurology at UCSF, and the first and co-lead author of the paper, which appears in Nature Medicine on Oct. 20. “It could be a gamechanger for how we understand and manage this disease.”
Researchers analyzed more than 5,000 proteins in blood samples from 134 people with MS, both before and after their diagnosis. These samples were provided by the U.S. Department of Defense Serum Repository, which stores samples from armed service members when they apply to join the military. The samples are then available for study decades afterwards, by which time some of the people may have gone on to develop MS.
Seven years before a person’s diagnosis, they saw a spike in a protein called MOG, which stands for myelin oligodendrocyte glycoprotein and indicates damage to the insulation around the wires of the nervous system. A year after the MOG spike appeared, they saw a spike in another protein called neurofilament light chain, which indicates damage to the wires themselves.
During this time, IL-3 and some related proteins that orchestrate an immune reaction appeared in the blood.
The team identified about 50 proteins that herald future disease, and they have submitted a patent application for a diagnostic blood test using the top 21 of them.
Ari Green, MD, chief of the Division of Neuroimmunology and Glial Biology in the UCSF Department of Neurology and senior author of the paper, said the study offers the hope of prevention and it gives a deeper understanding of what leads to the development of symptoms in MS.
"We now know that MS starts way earlier than the clinical onset, creating the real possibility that we could someday prevent MS — or at least use our understanding to protect people from further injury.”
Authors: Other UCSF authors are Gabriel Cerono, MD, Kiarra Ning, John Boscardin, PhD, The UCSF ORIGINS Study, Christian Cordano, MD, PhD, Asritha Tubati, Camille Fouassier, Eric D. Chow, PhD, Refujia Gomez, Adam Santaniello, Kelsey C. Zorn, MHS, Jill A. Hollenbach, PhD, MPH, Jorge R. Oksenberg, PhD, Bruce A.C. Cree, MD, PhD, MAS, Stephen L. Hauser, MD, Jonah R. Chan, PhD, Sergio E. Baranzini, PhD, Michael R. Wilson, MD, and Ari J. Green, MD. For all authors, see the paper.
Funding: This work was funded in part by the Department of Defense (HT94252310499), the National Institutes of Health (R01 NS105741 R01AG062562 R01AG038791, 1S10OD028511-01, R35NS111644, the Valhalla Foundation, the National MS Society, the Westridge Foundation, the National Multiple Sclerosis Society (RFA-2104-37504, SI-2001-35751), the Water Cove Charitable Foundation, Tim and Laura O’Shaughnessy, and the Littera Family. For all funding and disclosures, see the paper.
About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF's primary academic medical center, includes top-ranked specialty hospitalsand other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at ucsf.edu, or see our Fact Sheet.
###
Follow UCSF
ucsf.edu | Facebook.com/ucsf | YouTube.com/ucsf
END
How multiple sclerosis harms a brain long before symptoms appear
2025-10-20
ELSE PRESS RELEASES FROM THIS DATE:
Did marine life in the palaeocene use a compass?
2025-10-20
Some ancient marine organisms produced mysterious magnetic particles of unusually large size, which can now be found as fossils in marine sediments. An international team has succeeded in mapping the magnetic domains on one of such ‘giant magnetofossils’ using a sophisticated method at the Diamond X-ray source. Their analysis shows that these particles could have allowed these organisms to sense tiny variations in both the direction and intensity of the Earth’s magnetic field, enabling them to geolocate themselves and ...
About 9 in 10 haven’t heard of condition that affects nearly 90% of U.S. adults
2025-10-20
Embargoed until 4 a.m. CT / 5 a.m. ET Monday, Oct. 20, 2025
DALLAS, Oct. 20, 2025 — About 9 in 10 U.S. adults have not heard of cardiovascular-kidney-metabolic (CKM) syndrome, a newly defined health condition affecting nearly 90% of adults that includes heart disease, kidney disease, diabetes and obesity, according to a new survey from the American Heart Association, a relentless force changing the future of health for everyone everywhere. However, many are interested in learning more about it.
Nearly 90% of U.S. adults have at least ...
Personalized brain stimulation offers new hope for people with hard-to-treat epilepsy
2025-10-20
PITTSBURGH, October 20, 2025 — Doctors and researchers at the University of Pittsburgh and UPMC have developed a new treatment for epilepsy patients who don’t respond to medication and aren’t candidates for surgery. Their approach, published today in Nature Communications, uses deep brain stimulation (DBS) that is tailored to each patient’s unique brain wiring.
Epilepsy affects more than 50 million people worldwide, and about a third of those do not respond to medication. For some, seizures are generated in parts of the brain that control essential functions – speech, movement or vision – that can’t be safely removed. Brain ...
The tiny droplets that bounce without bursting
2025-10-20
If you’ve ever added liquid to a hot frying pan, maybe you noticed how the droplets bubbled up and skittered across the sizzling surface, rather than immediately flattening and wetting. This happens because the pan’s heat starts boiling the undersides of the droplets, producing vapor that acts as an insulating cushion on which they can – momentarily – dance.
Previously, scientists have produced a room-temperature version of this phenomenon – known as the Leidenfrost effect – ...
Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer
2025-10-20
Note: Abstract #6267, titled ECOG-ACRIN EA6174: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, is scheduled to be presented during the European Society for Medical Oncology meeting on Monday, Oct. 20, at 2:30 a.m. ET in the Cologne Auditorium, Messe Berlin, Berlin.
A drug that harnesses the immune system to attack cancer cells has proved successful in preventing a rare and aggressive form of skin cancer from spreading to other organs when given immediately after surgery, a new study shows.
Led by researchers at NYU ...
Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer
2025-10-20
A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body’s immune system to target and eliminate cancer cells appeared to reduce the risk of distant metastases for an aggressive form of skin cancer when given immediately after surgery, but did not significantly reduce the overall risk of recurrence, which was a co-primary endpoint of the trial. The randomized phase 3 STAMP trial (EA6174) is the largest clinical study to date evaluating pembrolizumab, ...
What is the extent of disparities in cancer clinical trials among low- and middle-income countries?
2025-10-20
New research reveals that the number and complexity of cancer clinical trials since 2001 have varied across low- and middle-income countries (LMICs), with economic growth contributing to disparities, but only to a certain extent. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
Although LMICs are expected to experience the greatest global burden of cancer in the coming years, cancer clinical trials are disproportionally concentrated in high-income countries. Because evidence suggests that LMICs have increased the number of cancer clinical trials over the last few decades, researchers investigated disparities ...
Invisible poison: Airborne mercury from gold mining is contaminating African food crops, new study warns
2025-10-20
In a recent study published today in the European Geosciences Union (EGU) journal Biogeosciences, scientists have confirmed that mercury pollution from artisanal and small-scale gold mining (ASGM) is contaminating food crops not through the soil, as previously believed, but directly from the air. Driven by the surging price of gold, which has increased by more than tenfold since 2000, the rapid expansion of unregulated mining in these regions raises urgent questions about food security, human health, and environmental justice
The study, conducted by an international team of scientists led by Excellent ...
Nearly half of Finns with chronic conditions find medication therapy a burden
2025-10-20
According to a recent study, 44% of people with chronic conditions who responded to a population-based survey experienced medication-related burden (MRB). The burden was most common among people with diabetes, heart disease, rheumatic disease or some other musculoskeletal disorder. The greatest burden was caused by factors associated with health care, such as fragmented care and the cost of medicines, as well as adverse drug reactions or concerns about them.
“Other factors linked with MRB were poor health status, limits on functional capacity and low income,” says Pharmacist and Doctoral Researcher Heidi Mikkola from the School of Pharmacy at the University of ...
Do animals fall for optical illusions? What fish and birds can teach us about perception
2025-10-20
Have you ever looked at two circles of exactly the same size and sworn one was larger? If so, your eyes have been tricked by the Ebbinghaus illusion, a classic example of how context can shape what we see. Place a circle among other smaller circles, and it seems bigger; place it among larger ones, and it shrinks before our eyes. This illusion fascinates psychologists because it reveals that perception is not a mirror of the outside world but a clever construction of the brain.
But here is the question that inspired our study: do other animals fall for the same tricks? If a tiny fish or a bird perceives ...